All News
Xeljanz Cancer Risks Detailed
MedPage Today
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Read Article
Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis
Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.
Read Article
The Top 10 Research Priorities in Psoriatic Arthritis
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
Read Article
Comparing Biosimilar Growth in the US, Germany, and Switzerland
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe.
Read Article
NEJM Clinical Images: 74-yoF with psoriatic arthritis has swelling of the fifth finger; found to have nontender, subcutaneous nodules in the hypothenar region and over the fifth finger. https://t.co/ugfFGZ0CWh https://t.co/a5q1TWRqMM
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0zCcYXMQOD
#BestOf2022
Links:
Dr. John Cush RheumNow ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/6uUWYPyFKf https://t.co/9nVj0lYwMO
Links:
Dr. John Cush RheumNow ( View Tweet)
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/qpGYDguYBK https://t.co/KUNQrSBNO2
Links:
Dr. John Cush RheumNow ( View Tweet)
Get the Skinny on Bimekizumab in PsA
Dr. Janet Pope discusses abstract presented at #ACR22.
https://t.co/FKFARxQ2fa https://t.co/wSyXeSHII3
Links:
Dr. John Cush RheumNow ( View Tweet)
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies
Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease.
https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab Efficacy in TNF-Refractory PsA
Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors.
https://t.co/78whpnLkhd https://t.co/yxwSGR3hTV
Links:
Dr. John Cush RheumNow ( View Tweet)
The Top 10 Research Priorities in Psoriatic Arthritis
A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).
https://t.co/qvcB3OkJUS https://t.co/EuD3qhOb5a
Links:
Dr. John Cush RheumNow ( View Tweet)
From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab
Links:
Dr. John Cush RheumNow ( View Tweet)
Oligoarticular PsA: FOREMOST Study
Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study
https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk
Links:
Dr. John Cush RheumNow ( View Tweet)
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx
Links:
Dr. John Cush RheumNow ( View Tweet)
Sleep Quality & PsA
Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire.
https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Links:
Dr. John Cush RheumNow ( View Tweet)
Differences in Presentation and Outcomes of Early vs Late Onset PsA
Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies
https://t.co/3dwYmx7Hva https://t.co/ZFlFmWRbMK
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of #ACR22 Day 2 in PSA
-Efficacy and Safety Results from BE OPTIMAL in PsA
-JAK inhibitors in rheumatic diseases
-Who is the Winner? Switch vs Cycle in PsA
-Women vs. Men: Response to Treatment in Seronegative Arthritis
and more.
https://t.co/JSKafxioMT https://t.co/Ov0VuCdX5y
Links:
Dr. John Cush RheumNow ( View Tweet)
Topic Podcasts - PsA Part1
Best of PsA on Day 1 #ACR22
https://t.co/uXxUwy6u9G https://t.co/GDDXgcn2EC
Links:
Dr. John Cush RheumNow ( View Tweet)
